Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab

Inclusion Criteria: * Patients currently treated at the University of Mississippi Medical Center Oncology Clinic * Patient is being treated with bevacizumab either alone or in combination with other agents for cancer * Patient blood pressure is \>140 mmHg (systolic) or \> 90 mmHg (diastolic), either treated or untreated with medications for hypertension * Patients may be currently on medications for hypertension (other than Beta blocker, ACEI, or ARB); these will be continued at the same dose throughout the study * Patients should be \> 18 years of age * Patients receiving bevacizumab therapy approximately every 2 weeks Exclusion Criteria: * History of ACEI or ARB induced angioedema or idiopathic/hereditary angioedema * Patient currently treated with a Beta blocker, ACEI, or ARB or have a history of intolerance to a medication in any of these classes * Hyperkalemia, defined as a potassium value of \>5 mEq/L * Pregnancy or breastfeeding * Severe renal impairment (eGFR \<30 mL/min) * Moderate hepatic impairment as identified by physician * Currently taking CYP2D6 inducers (rifampin, carbamazepine or dexamethasone) or inhibitors (bupropion, fluoxetine, paroxetine, duloxetine, etc.) * History of clinically significant EKG abnormality which would contraindicate beta blocker use * Recent stroke (\<6 months) * Recent myocardial infarction (\<6 months) * Congestive heart failure * Severe asthma or COPD * Diagnosed obstructive sleep apnea